Press releases
- Veracyte Announces Key Milestone in Companion Diagnostics Program With Acerta Pharma Using LymphMark Lymphoma Subtyping Test
- Veracyte to Present at 20th Annual Needham Virtual Healthcare Conference
- Veracyte Appoints Muna Bhanji to Its Board of Directors
- Veracyte Completes Acquisition of Decipher Biosciences
- Veracyte Commends New USPSTF Lung Cancer Screening Guidelines
- Veracyte to Present at 10th Annual SVB Leerink Global Healthcare Conference
- Veracyte Announces Fourth Quarter and Full-Year 2020 Financial Results
- Veracyte to Present at BTIG Virtual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
- Veracyte to Release Fourth Quarter and Full-Year 2020 Financial Results on February 17, 2021
- Veracyte Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares
More ▼
Key statistics
On Thursday, Veracyte Inc (12V:DEU) closed at 46.40, -32.26% below its 52-week high of 68.50, set on Feb 09, 2021.
52-week range
Markit short selling activity
Open | 43.20 |
---|---|
High | 46.40 |
Low | 43.20 |
Bid | 46.60 |
Offer | 46.80 |
Previous close | 46.20 |
Average volume | 105.11 |
---|---|
Shares outstanding | 67.00m |
Free float | 64.72m |
P/E (TTM) | -- |
Market cap | 3.59bn USD |
EPS (TTM) | -0.6686 USD |
Data delayed at least 15 minutes, as of Apr 15 2021 16:10 BST.
More ▼